Advanced imaging of multiple myeloma bone disease

Barry Hansford, Rebecca Silbermann

Research output: Contribution to journalShort survey

1 Citation (Scopus)

Abstract

Multiple myeloma (MM), a malignancy of mature plasma cells, is the second most common hematologic malignancy and the most frequent cancer to involve the skeleton (1, 2). Bone disease in MM patients is characterized by lytic bone lesions that can result in pathologic fractures and severe pain. While recent advances in MM therapy have significantly increased the median survival of newly diagnosed patients (3), skeletal lesions and their sequelae continue to be a major source of patient morbidity and mortality and bone pain is the most frequent presenting symptom of MM patients (4). Rapid improvements in imaging technology now allow physicians to identify ever smaller skeletal and bone marrow abnormalities, however the clinical value of subtle radiographic findings is not always clear. This review summarizes currently available technologies for assessing MM bone disease and provides guidance for how to choose between imaging modalities.

Original languageEnglish (US)
Article number436
JournalFrontiers in Endocrinology
Volume9
Issue numberAUG
DOIs
StatePublished - Aug 7 2018

Fingerprint

Bone Diseases
Multiple Myeloma
Technology
Bone and Bones
Pain
Spontaneous Fractures
Hematologic Neoplasms
Plasma Cells
Skeleton
Neoplasms
Bone Marrow
Morbidity
Physicians
Survival
Mortality

Keywords

  • CT imaging
  • Lytic bone disease
  • MRI imaging
  • Myeloma bone disease
  • PET imaging

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Advanced imaging of multiple myeloma bone disease. / Hansford, Barry; Silbermann, Rebecca.

In: Frontiers in Endocrinology, Vol. 9, No. AUG, 436, 07.08.2018.

Research output: Contribution to journalShort survey

@article{bdd6f4f488174a5ba585e408d5d0473b,
title = "Advanced imaging of multiple myeloma bone disease",
abstract = "Multiple myeloma (MM), a malignancy of mature plasma cells, is the second most common hematologic malignancy and the most frequent cancer to involve the skeleton (1, 2). Bone disease in MM patients is characterized by lytic bone lesions that can result in pathologic fractures and severe pain. While recent advances in MM therapy have significantly increased the median survival of newly diagnosed patients (3), skeletal lesions and their sequelae continue to be a major source of patient morbidity and mortality and bone pain is the most frequent presenting symptom of MM patients (4). Rapid improvements in imaging technology now allow physicians to identify ever smaller skeletal and bone marrow abnormalities, however the clinical value of subtle radiographic findings is not always clear. This review summarizes currently available technologies for assessing MM bone disease and provides guidance for how to choose between imaging modalities.",
keywords = "CT imaging, Lytic bone disease, MRI imaging, Myeloma bone disease, PET imaging",
author = "Barry Hansford and Rebecca Silbermann",
year = "2018",
month = "8",
day = "7",
doi = "10.3389/fendo.2018.00436",
language = "English (US)",
volume = "9",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - Advanced imaging of multiple myeloma bone disease

AU - Hansford, Barry

AU - Silbermann, Rebecca

PY - 2018/8/7

Y1 - 2018/8/7

N2 - Multiple myeloma (MM), a malignancy of mature plasma cells, is the second most common hematologic malignancy and the most frequent cancer to involve the skeleton (1, 2). Bone disease in MM patients is characterized by lytic bone lesions that can result in pathologic fractures and severe pain. While recent advances in MM therapy have significantly increased the median survival of newly diagnosed patients (3), skeletal lesions and their sequelae continue to be a major source of patient morbidity and mortality and bone pain is the most frequent presenting symptom of MM patients (4). Rapid improvements in imaging technology now allow physicians to identify ever smaller skeletal and bone marrow abnormalities, however the clinical value of subtle radiographic findings is not always clear. This review summarizes currently available technologies for assessing MM bone disease and provides guidance for how to choose between imaging modalities.

AB - Multiple myeloma (MM), a malignancy of mature plasma cells, is the second most common hematologic malignancy and the most frequent cancer to involve the skeleton (1, 2). Bone disease in MM patients is characterized by lytic bone lesions that can result in pathologic fractures and severe pain. While recent advances in MM therapy have significantly increased the median survival of newly diagnosed patients (3), skeletal lesions and their sequelae continue to be a major source of patient morbidity and mortality and bone pain is the most frequent presenting symptom of MM patients (4). Rapid improvements in imaging technology now allow physicians to identify ever smaller skeletal and bone marrow abnormalities, however the clinical value of subtle radiographic findings is not always clear. This review summarizes currently available technologies for assessing MM bone disease and provides guidance for how to choose between imaging modalities.

KW - CT imaging

KW - Lytic bone disease

KW - MRI imaging

KW - Myeloma bone disease

KW - PET imaging

UR - http://www.scopus.com/inward/record.url?scp=85054929705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054929705&partnerID=8YFLogxK

U2 - 10.3389/fendo.2018.00436

DO - 10.3389/fendo.2018.00436

M3 - Short survey

VL - 9

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - AUG

M1 - 436

ER -